Patients were treated with adalimumab and evaluated for up to @weeks as @ data cohorts : the all-adalimumab cohort ( patients receiving @ injection of adalimumab ) , the @-week follow-up subcohort ( patients who completed @weeks of follow-up after the first adalimumab dose ) , and the dose-escalation subcohort ( patients receiving adalimumab doses that increased to @mg every other week ) .